1-3 of 3
Jarmila Kissova
Close
Sort by
Journal Articles

Low-Burden TP53 Mutations Occur in Chronic Phase of Myeloproliferative Neoplasms Regardless of Hydroxyurea Administration, Disease Type, and JAK2 Status

Blanka Kubesova, MSc, Sarka Pavlova, PhD, Jitka Malcikova, PhD, Jitka Kabathova, MSc, Lenka Radova, PhD, Nikola Tom, MSc, Boris Tichy, PhD, Karla Plevova, PhD, Barbara Kantorova, PhD, Kristyna Fiedorova, MSc, Jarmila Kissova, PhD, Bettina Gisslinger, Heinz Gisslinger, Jiri Mayer, MD, Robert Kralovics, Sarka Pospisilova, Michael Doubek
Journal: Blood
Blood (2016) 128 (22): 4284.
https://doi.org/10.1182/blood.V128.22.4284.4284
Published: 2016
Journal Articles

Prognostic Significance of Morphological Evaluation of Tumor Cells in Multiple Myeloma.

Mohammed Al-sahmani, MD, Irena Trnavska, Monika Antosova, Libuse Antosova, Jarmila Kissova, MD, Hana Filkova, M.Sc., Jan Smetana, M.Sc., Zdenek Adam, MD, Prof., Ludek Pour, MD, Marta Krejci, MD, Lenka Zahradova, MD, Alena Bulikova, MD, Miroslav Penka, Prof., Petr Kuglik, Ass., Prof., Roman Hajek, MD, Prof.
Journal: Blood
Blood (2009) 114 (22): 4889.
https://doi.org/10.1182/blood.V114.22.4889.4889
Published: 2009
Journal Articles

JAK2 Mutation and Additional Thrombophilic Markers Predispose to Thrombosis in Myeloproliferative Diseases with Thrombocythemia

Miroslav Penka, Jiri Schwarz, Michael Doubek, MD, PhD, Petr Dulicek, Karel Indrak, Yvona Brychtova, MD, Antonin Hlusí, Jarmila Kissova, Jiri Mayer, MD, Tomas Pavlik
Journal: Blood
Blood (2008) 112 (11): 5257.
https://doi.org/10.1182/blood.V112.11.5257.5257
Published: 2008